JP2015509945A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509945A5 JP2015509945A5 JP2014558870A JP2014558870A JP2015509945A5 JP 2015509945 A5 JP2015509945 A5 JP 2015509945A5 JP 2014558870 A JP2014558870 A JP 2014558870A JP 2014558870 A JP2014558870 A JP 2014558870A JP 2015509945 A5 JP2015509945 A5 JP 2015509945A5
- Authority
- JP
- Japan
- Prior art keywords
- changed
- ala
- composition
- asp
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 18
- 108010062877 Bacteriocins Proteins 0.000 claims 14
- 241000894006 Bacteria Species 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 5
- 108010085774 MU1140 Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- CXTXHTVXPMOOSW-JUEJINBGSA-N epidermin Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSC[C@H](C(N[C@@H](CCCCN)C(=O)N1)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@H]1C(N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CS[C@H]1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N\C(=C/C)C(=O)NCC(=O)N[C@H]1C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@H](C(N\C=C/SC2)=O)CSC1)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 CXTXHTVXPMOOSW-JUEJINBGSA-N 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- GDSYPXWUHMRTHT-UHFFFAOYSA-N Epidermin Natural products N#CCC(C)(C)OC1OC(CO)C(O)C(O)C1O GDSYPXWUHMRTHT-UHFFFAOYSA-N 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 235000013361 beverage Nutrition 0.000 claims 2
- 230000035587 bioadhesion Effects 0.000 claims 2
- 239000000551 dentifrice Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 108010064962 epidermin Proteins 0.000 claims 2
- 108010047651 gallidermin Proteins 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007913 intrathecal administration Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 102220628388 Annexin A10_F1Y_mutation Human genes 0.000 claims 1
- 102220546214 Cell division cycle-associated protein 2_W4D_mutation Human genes 0.000 claims 1
- 101100205180 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-6 gene Proteins 0.000 claims 1
- 108010053775 Nisin Proteins 0.000 claims 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 claims 1
- 101001138042 Streptococcus mutans Lantibiotic mutacin-1140 Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000000022 bacteriostatic agent Substances 0.000 claims 1
- 239000003518 caustics Substances 0.000 claims 1
- RKLXDNHNLPUQRB-TVJUEJKUSA-N chembl564271 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]2C(C)SC[C@H](N[C@@H](CC(N)=O)C(=O)NC(=O)[C@@H](NC2=O)CSC1C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NC(=C)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H]1NC(=O)C(=C\C)/NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]2NC(=O)CNC(=O)[C@@H]3CCCN3C(=O)[C@@H](NC(=O)[C@H]3N[C@@H](CC(C)C)C(=O)NC(=O)C(=C)NC(=O)CC[C@H](NC(=O)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=4C5=CC=CC=C5NC=4)CSC3)C(O)=O)C(C)SC2)C(C)C)C(C)SC1)C1=CC=CC=C1 RKLXDNHNLPUQRB-TVJUEJKUSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000004744 fabric Substances 0.000 claims 1
- AHMZTHYNOXWCBS-PCUVAHMGSA-N gallidermin Chemical compound C([C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CSC[C@H](C(N[C@@H](CCCCN)C(=O)N1)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@H]1C(N2CCC[C@H]2C(=O)NCC(=O)N[C@H](CS[C@H]1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N\C(=C\C)C(=O)NCC(=O)N[C@H]1C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](C(N/C=C/SC2)=O)CSC1)=O)=O)C1=CC=CC=C1 AHMZTHYNOXWCBS-PCUVAHMGSA-N 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- NTIBMIIYTKPBNR-UHFFFAOYSA-N methoxymethyl 2-hydroxybenzoate Chemical compound COCOC(=O)C1=CC=CC=C1O NTIBMIIYTKPBNR-UHFFFAOYSA-N 0.000 claims 1
- 108010035837 mutacin B-Ny266 Proteins 0.000 claims 1
- 108010093400 mutacin I Proteins 0.000 claims 1
- SUJOIPVTNUVDCB-UHFFFAOYSA-N mutactin Natural products CC1=CC(O)=C2C(=O)CC(O)CC2=C1C1=CC(O)=CC(=O)O1 SUJOIPVTNUVDCB-UHFFFAOYSA-N 0.000 claims 1
- 239000004309 nisin Substances 0.000 claims 1
- 235000010297 nisin Nutrition 0.000 claims 1
- 239000004745 nonwoven fabric Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 108010037687 staphylococcin Proteins 0.000 claims 1
- 239000003206 sterilizing agent Substances 0.000 claims 1
- 108010043542 streptin Proteins 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 108010082567 subtilin Proteins 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 239000002759 woven fabric Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603693P | 2012-02-27 | 2012-02-27 | |
| US201261603661P | 2012-02-27 | 2012-02-27 | |
| US61/603,693 | 2012-02-27 | ||
| US61/603,661 | 2012-02-27 | ||
| PCT/US2013/027336 WO2013130349A1 (en) | 2012-02-27 | 2013-02-22 | Variants of the lantibiotic mu1140 and other lantibiotics with improved pharmacological properties and structural features |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509945A JP2015509945A (ja) | 2015-04-02 |
| JP2015509945A5 true JP2015509945A5 (https=) | 2016-04-07 |
| JP6309902B2 JP6309902B2 (ja) | 2018-04-11 |
Family
ID=49083172
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558870A Active JP6309902B2 (ja) | 2012-02-27 | 2013-02-22 | ランチビオティクスｍｕ１１４０および改善された薬理学的特性および構造的特徴を有する他のランチビオティクスの変異体 |
| JP2014558872A Expired - Fee Related JP6297506B2 (ja) | 2012-02-27 | 2013-02-22 | 齲歯のための置換療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558872A Expired - Fee Related JP6297506B2 (ja) | 2012-02-27 | 2013-02-22 | 齲歯のための置換療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9260488B2 (https=) |
| EP (3) | EP2833902A4 (https=) |
| JP (2) | JP6309902B2 (https=) |
| CN (2) | CN104302307B (https=) |
| AU (2) | AU2013226404B2 (https=) |
| BR (2) | BR112014020659A2 (https=) |
| CA (2) | CA2865395A1 (https=) |
| HK (2) | HK1205519A1 (https=) |
| MX (2) | MX369443B (https=) |
| WO (2) | WO2013130351A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019529344A (ja) * | 2016-07-15 | 2019-10-17 | イントレキソン コーポレーション | ランチビオティックバリアントおよびその使用 |
| US10577399B2 (en) | 2016-10-28 | 2020-03-03 | The Texas A&M University System | Modified lantibiotics and methods of making and using the modified lantibiotics |
| CN113039196B (zh) | 2018-10-31 | 2025-03-18 | 株式会社村田制作所 | 抗革兰氏阴性菌化合物 |
| CU24691B1 (es) * | 2018-11-01 | 2024-01-10 | Biofouling Tech Inc | Dispositivo y método para reducir la bioincustración sobre un sustrato parcial o totalmente sumergido en un ambiente acuoso |
| CA3128389A1 (en) * | 2019-03-08 | 2020-09-17 | Fraunhofer Usa, Inc. | Novel antimicrobial lantibiotic peptide and uses thereof |
| CN118490568B (zh) * | 2024-07-16 | 2024-10-18 | 南昌怀特科技有限公司 | 一种用于牙齿美白的抑菌凝胶及其制备方法与应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4366246A (en) | 1977-11-08 | 1982-12-28 | Genentech, Inc. | Method for microbial polypeptide expression |
| US5516682A (en) * | 1988-07-05 | 1996-05-14 | University Of Maryland | Subtilin variant of enhanced stability and activity |
| GB9423404D0 (en) * | 1994-11-19 | 1995-01-11 | Biotech & Biolog Scien Res | Production of nisin |
| US6964760B2 (en) * | 1997-06-10 | 2005-11-15 | University Of Florida Research Foundation | Antimicrobial polypeptide, nucleic acid, and methods of use |
| US20060198793A1 (en) * | 1997-06-10 | 2006-09-07 | University Of Florida Research Foundation | Antimicrobial polypeptide, nucleic acid, and methods of use |
| US5932469A (en) * | 1997-06-10 | 1999-08-03 | University Of Florida | Antimicrobial polypeptide, nucleic acid, and methods of use |
| US6251478B1 (en) | 1999-12-22 | 2001-06-26 | Balchem Corporation | Sensitive substance encapsulation |
| EP1483366B1 (en) * | 2002-02-22 | 2010-04-14 | Blis Technologies Limited | Antimicrobial composition |
| AU2006279749B2 (en) | 2005-08-12 | 2012-12-20 | Oragenics, Inc. | Differentially protected orthogonal lanthionine technology |
| US20090215985A1 (en) * | 2005-08-12 | 2009-08-27 | Oragenics, Inc. | Differentially protected orthogonal lanthionine technology |
| WO2007044745A1 (en) * | 2005-10-11 | 2007-04-19 | Biosynexus Incorporated | Lantibiotic and mupirocin compositions for treating bacterial infections |
| CA2690267A1 (en) * | 2007-06-12 | 2008-12-18 | The University Of British Columbia | Small cationic antimicrobial peptides |
| DK2176284T3 (da) * | 2007-07-20 | 2013-10-14 | Univ Minnesota | Lantibiotika og anvendelser deraf |
| IE20080365A1 (en) * | 2008-05-09 | 2010-03-16 | Univ College Cork Nat Univ Ie | Nisin derivatives and the use thereof |
-
2013
- 2013-02-22 CN CN201380011187.9A patent/CN104302307B/zh not_active Expired - Fee Related
- 2013-02-22 WO PCT/US2013/027340 patent/WO2013130351A1/en not_active Ceased
- 2013-02-22 US US14/381,524 patent/US9260488B2/en active Active
- 2013-02-22 EP EP13755353.3A patent/EP2833902A4/en not_active Withdrawn
- 2013-02-22 EP EP13755436.6A patent/EP2820036B1/en active Active
- 2013-02-22 JP JP2014558870A patent/JP6309902B2/ja active Active
- 2013-02-22 CA CA2865395A patent/CA2865395A1/en not_active Abandoned
- 2013-02-22 HK HK15106032.0A patent/HK1205519A1/xx unknown
- 2013-02-22 CA CA2865405A patent/CA2865405C/en active Active
- 2013-02-22 BR BR112014020659A patent/BR112014020659A2/pt not_active IP Right Cessation
- 2013-02-22 US US14/381,420 patent/US9963488B2/en active Active
- 2013-02-22 AU AU2013226404A patent/AU2013226404B2/en not_active Ceased
- 2013-02-22 MX MX2014010151A patent/MX369443B/es active IP Right Grant
- 2013-02-22 HK HK15106033.9A patent/HK1205458A1/xx unknown
- 2013-02-22 BR BR112014020656A patent/BR112014020656A2/pt not_active Application Discontinuation
- 2013-02-22 EP EP17000662.1A patent/EP3219325B1/en active Active
- 2013-02-22 MX MX2014010143A patent/MX358060B/es active IP Right Grant
- 2013-02-22 CN CN201380011223.1A patent/CN104321338B/zh not_active Expired - Fee Related
- 2013-02-22 WO PCT/US2013/027336 patent/WO2013130349A1/en not_active Ceased
- 2013-02-22 JP JP2014558872A patent/JP6297506B2/ja not_active Expired - Fee Related
- 2013-02-22 AU AU2013226402A patent/AU2013226402B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509945A5 (https=) | ||
| TWI455721B (zh) | 癌疫苗組合物 | |
| US8828413B2 (en) | Peptoid oligomers, pharmaceutical compositions and methods of using the same | |
| US8901071B2 (en) | Compounds and their use | |
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| KR102224929B1 (ko) | 해삼에서 분리한 항균 펩타이드로부터 유래한 신규 항균 펩타이드 및 이의 용도 | |
| JP7219512B2 (ja) | 抗菌活性を有するポリペプチド、これを含む敗血症の予防または治療用組成物、および抗菌用組成物 | |
| JP2017526627A5 (https=) | ||
| JP2018512454A5 (https=) | ||
| JP2013518057A5 (https=) | ||
| JP6158713B2 (ja) | ヒトラクトフェリン由来ペプチド及びその使用 | |
| JP2015502974A5 (https=) | ||
| CN115244067A (zh) | 合成抗微生物肽 | |
| AU2020227591B2 (en) | Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising same, and antibacterial composition | |
| US11965006B2 (en) | Antimicrobial and anti-cancer therapy | |
| CA2706738A1 (en) | Treatment of mixed pathogen infections | |
| JP6309902B2 (ja) | ランチビオティクスｍｕ１１４０および改善された薬理学的特性および構造的特徴を有する他のランチビオティクスの変異体 | |
| PH12015502005B1 (en) | New stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy | |
| IL303954B2 (en) | FIMH mutants, their compositions and uses | |
| JP2009500045A5 (https=) | ||
| JP2019523220A5 (https=) | ||
| WO2009005798A3 (en) | Antifungal formulation and method of preparation | |
| EP2297195B9 (en) | Antibacterial peptides | |
| CN116947977B (zh) | 一种牙龈保护抗菌肽或其立体异构及其制备方法和应用 | |
| JP2019519466A5 (https=) |